ProQR Therapeutics N.V. (PRQR) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 7.95
30Y Low7.9·High7.9
P/B Ratio
↓
2.66
↓-29% vs avg
5yr avg: 3.76
30Y Low2.1·High5.8
ROE
↑
-58.8%
-2% vs avg
5yr avg: -57.7%
30Y Low-94%·High-21%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PRQR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ProQR Therapeutics N.V. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $152M | $213M | $216M | $160M | $265M | $514M | $210M | $407M | $537M | $82M | $114M |
| Enterprise Value | $61M | $134M | $84M | $51M | $192M | $387M | $159M | $296M | $441M | $41M | $61M |
| P/E Ratio → | -3.28 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 8.59 | 13.93 | 11.45 | 24.62 | 73.75 | 385.09 | 204.33 | 210.39 | 108.75 | — | 50.13 |
| P/B Ratio | 2.66 | 4.31 | 2.44 | 3.51 | 3.98 | 4.54 | 3.04 | 3.86 | 5.80 | 2.08 | 2.15 |
| P/FCF | — | — | — | 7.95 | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 7.44 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PRQR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.80 | 4.45 | 7.80 | 53.50 | 289.85 | 154.91 | 153.25 | 89.28 | — | 26.68 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | 2.52 | — | — | — | — | — | — | — |
PRQR Profitability
Margins and return-on-capital ratios measuring operating efficiency
ProQR Therapeutics N.V. earns an operating margin of -275.9%. Operating margins have expanded from -489.1% to -275.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -58.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.0% | 83.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -5943.6% | 80.1% | 165.5% | 43.8% |
| Operating Margin | -275.9% | -275.9% | -161.2% | -489.1% | -1813.0% | -4285.4% | -4117.4% | -2971.8% | -734.5% | 2648.7% | -1734.1% |
| Net Profit Margin | -265.2% | -265.2% | -146.9% | -431.7% | -1792.5% | -4549.8% | -4525.3% | -2935.6% | -746.7% | 2854.0% | -1713.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.8% | -58.8% | -41.4% | -50.0% | -71.6% | -66.6% | -53.4% | -57.3% | -55.9% | -94.4% | -54.7% |
| ROA | -28.9% | -28.9% | -17.3% | -17.4% | -33.8% | -36.8% | -36.8% | -46.9% | -45.2% | -73.6% | -47.2% |
| ROIC | — | — | — | — | — | -1945.1% | -480.7% | — | — | — | — |
| ROCE | -40.3% | -40.3% | -25.0% | -24.1% | -39.2% | -39.4% | -37.2% | -51.8% | -49.5% | -78.3% | -51.6% |
PRQR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $92M exceeds total debt of $14M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.19 | 0.48 | 0.33 | 0.53 | 0.61 | 0.14 | 0.10 | 0.18 | 0.11 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.59 | -1.49 | -2.40 | -1.09 | -1.12 | -0.73 | -1.05 | -1.04 | -1.04 | -1.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -5.43 | — | — | — | — | — | — | — |
| Interest Coverage | -48.66 | -48.66 | -24.96 | -22.12 | -11.50 | -16.82 | -24.90 | -159.14 | -44.78 | -67.95 | -69.16 |
Net cash position: cash ($92M) exceeds total debt ($14M)
PRQR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
ProQR Therapeutics N.V.'s current ratio of 3.09x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.54x to 3.09x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.09 | 3.09 | 3.95 | 3.54 | 7.36 | 6.94 | 7.77 | 10.43 | 13.28 | 5.95 | 9.24 |
| Quick Ratio | 3.09 | 3.09 | 3.95 | 3.54 | 7.36 | 6.94 | 7.77 | 10.43 | 13.17 | 5.94 | 9.07 |
| Cash Ratio | 2.85 | 2.85 | 3.84 | 3.48 | 4.52 | 6.80 | 7.36 | 10.18 | 12.94 | 5.66 | 8.82 |
| Asset Turnover | — | 0.14 | 0.11 | 0.04 | 0.02 | 0.01 | 0.01 | 0.01 | 0.04 | -0.03 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 1.09 | 13.72 | 1.10 |
| Days Sales Outstanding | — | 121.45 | — | 78.49 | 5713.05 | — | 347.21 | 252.23 | 91.82 | — | 250.32 |
PRQR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ProQR Therapeutics N.V. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | 12.6% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $105M | $82M | $81M | $72M | $64M | $50M | $41M | $34M | $25M | $23M |
Peer Comparison
Compare PRQR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PRQRYou | $152M | -3.3 | — | — | 83.0% | -275.9% | -58.8% | — | — |
 EDIT | $239M | -1.4 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 NTLA | $1B | -3.2 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CRSP | $5B | -7.8 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $3B | -36.3 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 ARWR | $10B | -6099.2 | 86.9 | 66.8 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 QURE | $2B | -7.8 | — | — | 89.5% | -1166.8% | -207.1% | -50.7% | — |
 RCKT | $290M | -1.3 | — | — | — | — | -60.3% | -62.4% | — |
 REPL | $712M | -2.8 | — | — | — | — | -62.6% | -51.9% | — |
 SLDB | $563M | -3.6 | — | — | — | — | -109.9% | -120.8% | — |
 RARE | $2B | -4.1 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
What if you invested $1,000 in PRQR 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in PRQR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PRQR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPRQR vs EDIT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Editas Medicine, Inc..
Compare NowPRQR — Frequently Asked Questions
Quick answers to the most common questions about buying PRQR stock.
What is ProQR Therapeutics N.V.'s P/E ratio?
ProQR Therapeutics N.V.'s current P/E ratio is -3.3x. This places it at the 50th percentile of its historical range.
What is ProQR Therapeutics N.V.'s ROE?
ProQR Therapeutics N.V.'s return on equity (ROE) is -58.8%. The historical average is -53.9%.
Is PRQR stock overvalued?
Based on historical data, ProQR Therapeutics N.V. is trading at a P/E of -3.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are ProQR Therapeutics N.V.'s profit margins?
ProQR Therapeutics N.V. has 83.0% gross margin and -275.9% operating margin.